

# **Financial Results**

Form Version 8 (Enhanced) Initiated by CS\_EPSILON ADVISORY SERVICES on 26/05/2010 03:46:36 PM Submitted by CS\_EPSILON ADVISORY SERVICES on 26/05/2010 06:12:05 PM Reference No CA-100526-56796

Submitted

Company Information	
Main Market Company	
New Announcement	
Submitting Investment Bank/Adviso applicable)	or (if
Submitting Secretarial Firm (if applicable)	EPSILON ADVISORY SERVICES SDN. BHD.
* Company name	TMC LIFE SCIENCES BERHAD
* Stock name	TMCLIFE
* Stock code	0101
* Contact person	Seow Fei San
* Designation	Company Secretary
* Contact number	03-78031126
E-mail address	micheleng@epsilonas.com

#### Part A: To be filled by Public Listed Company

		į
* Financial Year End	31/12/2010	
* Quarter	1 Qtr	-
* Quarterly report for the financial period ended	31/03/2010	
* The figures	have not been audited	

#### Please attach the full Quarterly Report here

₱ TMC Life Sciences Bhd Q12010.pdf PTMC LS note to the accounts Q12010.pdf

Remarks 

- DEFAULT CURRENCY OTHER CURRENCY

Currency	Malaysian Ringgit (MYR)

Part A2: SUMMARY OF KEY FINANCIAL INFORMATION

Summary of Key Financial Information for the financial period ended

	* 31	/03/2010			
	INDIVIDUAL	QUARTER	CUMULATIVE QUARTER		
	CURRENT YEAR QUARTER *	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE *	PRECEDING YEAR CORRESPONDING	
				PERIOD	
	31/03/2010	31/03/2009	31/03/2010	31/03/2009	
	[dd/mm/yyyy] \$\$'000	[dd/mm/yyyy] \$\$'000	[dd/mm/yyyy] \$\$'000	[dd/mm/yyyy] \$\$'000	
1. Revenue	12,368	10,178	12,368	10,178	
2. Profit/(loss) before tax	-2,595	-2,845	-2,595	-2,845	
3. Profit/(loss) for the period	-2,656	-2,829	-2,656	-2,829	

4. Profit/(loss) attributable to ordinary equity holders of the parent	-2,656	-2,829	-2,656	-2,829	
5. Basic earnings/(loss) per share (Subunit)	-0.43	-0.46	-0.43	-0.46	
6. Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00	
	AS AT END OF CURRENT QU	ARTER* AS AT	PRECEDING FINANCIAL	YEAR END	
7. Net assets per share attributable to ordinary equity holders of the parent (\$\$)		0.1667		0.1720	
Remarks:					

#### <u>Definition of Subunit:</u>

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit. Example for the subunit as follows:

Country	Base Unit	Subunit
Malaysia	Ringgit	Sen
United States	Dollar	Cent
United Kingdom	Pound	Pence

	INDIVIDUAL	INDIVIDUAL QUARTER CUMUL/				
	CURRENT YEAR QUARTER*	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE*	PRECEDING YEAR CORRESPONDING PERIOD		
	31/03/2010	31/03/2009	31/03/2010	31/03/2009		
	[dd/mm/yyyy] \$\$*000	[dd/mm/yyyy] \$\$'000	[dd/mm/yyyy] \$\$'000	[dd/mm/yyyy] \$\$'000		
1. Gross interest income	19	19	19	19		
2. Gross interest expense	636	431	636	431		
Remarks:						

Note: The above information is for the Exchange internal use only.





INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2010

Contact
No 11 Jalan Teknologi
Taman Sains Selangor 1
PJU 5, Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111 Fax: +603 6287 1212

www.tmclife.com 26/05/2010 16:56 www.tropicanamedicalcentre.com

# TMC LIFE SCIENCES BHD Company no. 624409-A

(Incorporated in Malaysia)

# INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2010

# CONDENSED CONSOLIDATED INCOME STATEMENT (UNAUDITED)

		<u>INDIVIDUA</u>	AL QUARTER	CUMULATIVE QUARTER		
•		CURRENT	PRECEDING YEAR	CURRENT	PRECEDING YEAR	
•		YEAR	CORRESPONDING	YEAR	CORRESPONDING	
•		QUARTER	QUARTER	TO-DATE	QUARTER	
4		31 Mar 2010	31 Mar 2009	31 Mar 2010	31 Mar 2009	
	Note	RM	RM	RM	RM	
Revenue		12,367,544	10,178,186	12,367,544	10,178,186	
Operating expenses		(12,309,802)	(10,903,187)	(12,309,802)	(10,903,187)	
Profit/(Loss) from operations	-	57,742	(725,001)	57,742	(725,001)	
Amortisation & depreciation		(2,034,616)	(1,708,443)	(2,034,616)	(1,708,443)	
Finance costs		(636,439)	(430,810)	(636,439)	(430,810)	
Interest income		18,570	19,438	18,570	19,438	
Share of loss of associate		(493)	-	(493)	-	
Loss before taxation	-	(2,595,236)	(2,844,816)	(2,595,236)	(2,844,816)	
Taxation	B5	(60,562)	15,345	(60,562)	15,345	
Loss after taxation	=	(2,655,798)	(2,829,471)	(2,655,798)	(2,829,471)	
ATTRIBUTABLE TO:					•	
Equity holders of the Company		(2,615,968)	(2,752,619)	(2,615,968)	(2,752,619)	
Minority interests	_	(39,830)	(76,852)	(39,830)	(76,852)	
	,	(2,655,798)	(2,829,471)	(2,655,798)	(2,829,471)	
(Loss) / Earnings per share (ser	٦)				•	
- Basic	B14	(0.43)	(0.46)	(0.43)	(0.46)	
- Diluted	_	N/A	N/A	N/A	N/A	

Note: N/A denotes Not Applicable

(The unaudited condensed consolidated income statements should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying notes attached to the interim financial report)

# INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2010

# CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

		<u>INDIVIDUA</u>	AL QUARTER	<b>CUMULATIVE QUARTER</b>		
		CURRENT	PRECEDING YEAR	CURRENT	PRECEDING YEAR	
		YEAR	CORRESPONDING	YEAR	CORRESPONDING	
		QUARTER	QUARTER	TO-DATE	QUARTER	
		31 Mar 2010	31 Mar 2009	31 Mar 2010	.31 Mar 2009	
	Note	RIVI	RM	RM	RM	
Loss after taxation		(2,655,798)	(2,829,471)	(2,655,798)	(2,829,471)	
Other comprehensive						
income/(loss)	_	-			-	
Total comprehensive loss for	ı					
the period	-	(2,655,798)	(2,829,471)	(2,655,798)	(2,829,471)	
Total comprehensive loss attributable to:						
Equity holders of the Company		(2,615,968)	(2,752,619)	(2,615,968)	(2,752,619)	
Minority interests	_	(39,830)	(76,852)	(39,830)	(76,852)	
	-	(2,655,798)	(2,829,471)	(2,655,798)	(2,829,471)	

(The unaudited condensed consolidated statements of compresive income should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying notes attached to the interim financial report)

# INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2010

AS AT   AT	CONDENSED CONSOLIDATED BALANCE SHEET		
Note   Note   RM   RM   RM			
ASSETS   Non-Current Assets   Property, plant and equipment   134,260,605   135,213,059   Long term trade receivables   1,472,251   3,331,190   3,331,190   3,331,190   3,331,190   3,331,190   1,472,251   1,472,251   1,472,251   1,472,251   1,472,251   1,472,251   1,472,251   1,472,251   1,472,251   1,475,783   12,528,472   1,476,783   151,288,842   151,476,783   151,288,842   1,476,783   151,288,842   1,476,783   1,476,7			
Non-Current Assets	Note		•
Property, plant and equipment	**		
Concept			
Socion   S			135,213,059
Intangible assets   12,197,109   12,528,472   Investment in associate   216,121   Investment in associate   151,476,783   151,288,842   Current Assets   151,476,783   4,053,684   3,627,209   Trade receivables   4,722,030   6,358,070   Other receivables, deposits and prepayments   1,764,598   2,186,283   Other investment   2,126,799   2,510,682   Tax refundable   2,661,414   2,517,119   Cash and cash equivalents   3,428,264   5,263,841   TOTAL ASSETS   18,754,789   22,463,214   TOTAL ASSETS   18,754,789   22,463,214   TOTAL ASSETS   18,754,789   22,463,214   TOTAL ASSETS   173,752,056   TOTAL Equity Attributable To Equity Holders Of The Company   Share capital   60,177,975   60,177,975   Share premium   21,751,724   21,751,724   Exchange rate reserve   (1,469)   (3,217)   Retained profits   18,300,625   103,421,817   Minority interests   74,198   114,028   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845   Total Equity Attributable Total Equity At			
Investment in associate			
Current Assets         151,476,783         151,288,842           Inventories         4,053,684         3,627,209           Trade receivables deposits and prepayments         4,722,030         6,358,070           Other receivables, deposits and prepayments         1,764,598         2,186,283           Other investment         2,212,799         2,510,682           Tax refundable         2,661,414         2,517,119           Cash and cash equivalents         18,754,789         22,463,214           TOTAL ASSETS         170,231,572         173,752,056           EQUITY AND LIABILITIES         Equity Attributable To Equity Holders Of The Company         60,177,975         60,177,975           Share premium         21,751,724         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,525         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         383,753         413,109           Term loan         3,656,478         40,318,836           <			
Inventories   4,053,684   3,627,209     Inventories   4,722,030   6,358,070     Other receivables   4,722,030   6,358,070     Other receivables, deposits and prepayments   1,784,598   2,186,283     Other investment   2,126,799   2,510,682     Tax refundable   2,661,414   2,517,119     Cash and cash equivalents   3,428,264   5,283,851     TOTAL ASSETS   170,231,572   173,752,056     EQUITY AND LIABILITIES     Equity Attributable To Equity Holders Of The Company     Share capital   60,177,975   60,177,975     Share premium   21,751,724   21,751,724     Exchange rate reserve   1,469   (3,217,747)     Cate of the property of the company   100,310,953     Total Equity Attributable To Equity Holders Of The Company   100,310,953     Total Equity Attributable To Equity Holders Of The Company   100,310,953     Total Equity Attributable To Equity Holders Of The Company   100,310,953     Total Equity Attributable To Equity Holders Of The Company   100,310,953     Total Equity Attributable To Equity Holders Of The Company   100,310,953     Total Equity Attributable To Equity Holders Of The Company   100,310,953     Total Equity Attributable To Equity Holders Of The Company	Investment in associate		
Inventories	Command 4 4-	151,476,783	151,288,842
Trade receivables         4,722,030         6,358,070           Other receivables, deposits and prepayments         1,764,598         2,186,283           Other investment         2,126,799         2,510,682           Tax refundable         2,661,414         2,517,119           Cash and cash equivalents         3,426,264         5,263,851           TOTAL ASSETS         170,231,572         173,752,056           EQUITY AND LIABILITIES         Equity Attributable To Equity Holders Of The Company         60,177,975         60,177,975           Share premium         21,751,724         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,625         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,963         103,535,845           Non-Current Liabilities         383,753         413,109           Term loan         38,656,478         40,318,838           Hire purchase         39,23,814         5,412,365           Other payables         11,348,180         10,380,197           Term loan		4.050.604	2 627 400
Other receivables, deposits and prepayments         1,764,598         2,186,283           Other investment         2,126,799         2,510,682           Tax refundable         2,661,414         2,517,119           Cash and cash equivalents         3,426,264         5,263,851           TOTAL ASSETS         18,754,789         22,463,214           TOTAL ASSETS         170,231,572         173,752,056           EQUITY AND LIABILITIES         Equity Attributable To Equity Holders Of The Company         60,177,975         60,177,975           Share capital         60,177,975         60,177,975         Share premium         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)         Retained profits         18,308,625         21,495,335           Total Equity         100,236,755         103,421,817         Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         38,656,478         40,318,838           Term loan         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           Te	•••		
Other investment         2,126,799         2,510,882           Tax refundable         2,661,414         2,517,119           Cash and cash equivalents         3,426,264         5,263,851           TOTAL ASSETS         18,754,789         22,463,214           TOTAL ASSETS         173,752,056           EQUITY AND LIABILITIES         Fequity Attributable To Equity Holders Of The Company           Share capital         60,177,975         60,177,975           Share premium         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,525         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         383,753         413,109           Term loan         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           Current Liabilities         3,923,814         5,412,385           Other payables         11,348,180 <td< td=""><td></td><td></td><td></td></td<>			
Tax refundable Cash and cash equivalents         2,661,414 2,517,119 3,428,264 5,263,851 18,754,789 22,463,214         3,428,264 5,263,851 18,754,789 22,463,214           TOTAL ASSETS         170,231,572 173,752,056           EQUITY AND LIABILITIES         Equity Attributable To Equity Holders Of The Company Share capital 60,177,975 60,177,975 Share premium 21,751,724 21,751,724 21,751,724 Exchange rate reserve (1,469) (3,217) Retained profits 18,308,525 21,495,335 Total Equity 100,236,755 103,421,817 Minority interests 74,198 114,028 Total Equity Attributable To Equity Holders Of The Company 100,310,953 103,535,845         Non-Current Liabilities 74,198 114,028 103,535,845           Non-Current Liabilities         383,753 413,109 2,29,167 3,229,167 3,229,167         3,229,167 3,229,167           Current Liabilities         3,923,814 5,412,385 Other payables 0,13,48,180 10,380,197 Term loan 7,486,455 7,678,563 Hire purchase 112,604 112,604 Bank overdraft 4,780,168 2,671,290 Tax payable 27,651,221 26,255,097 TOTAL LIABILITIES         27,651,221 26,255,097 TOTAL LIABILITIES         27,651,221 26,255,097 TOTAL LIABILITIES         170,231,572 173,752,056	· · · · · · · · · · · · · · · · · · ·		
Cash and cash equivalents         3,426,264         5,263,851           TOTAL ASSETS         18,754,789         22,463,214           TOTAL ASSETS         170,231,572         173,752,056           EQUITY AND LIABILITIES         8         170,231,572         173,752,056           Equity Attributable To Equity Holders Of The Company         60,177,975         60,177,975         Share capital         60,177,975         60,177,975         Share premium         21,751,724 <td< td=""><td>* *// ···· =···</td><td></td><td></td></td<>	* *// ···· =···		
TOTAL ASSETS   18,754,789   22,463,214   170,231,572   173,752,056	1 == 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1		
TOTAL ASSETS         173,752,056           EQUITY AND LIABILITIES           Equity Attributable To Equity Holders Of The Company         Share capital         60,177,975         60,177,975         Share premium         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,724         21,751,725         21,495,335           Total Equity Interests         74,198         114,028           Term loan         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167         3,229,167	Oddir and Casif equivalones		
EQUITY AND LIABILITIES           Equity Attributable To Equity Holders Of The Company         60,177,975         60,177,975           Share capital         60,177,975         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,525         21,495,335         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         383,753         413,109           Term loan         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           42,269,398         43,961,114           Current Liabilities         3,923,814         5,412,385           Other payables         3,923,814         5,412,385           Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168	TOTAL ASSETS		
Share capital   60,177,975   60,177,975   Share capital   21,751,724   21,751,724   Exchange rate reserve   (1,469)   (3,217)   Retained profits   18,308,525   21,495,335   Total Equity   100,236,755   103,421,817   Minority interests   74,198   114,028   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845		, , , , , , , , , , , , , , , , , , , ,	
Share capital   60,177,975   60,177,975   Share capital   21,751,724   21,751,724   Exchange rate reserve   (1,469)   (3,217)   Retained profits   18,308,525   21,495,335   Total Equity   100,236,755   103,421,817   Minority interests   74,198   114,028   Total Equity Attributable To Equity Holders Of The Company   100,310,953   103,535,845	EQUITY AND LIABILITIES		
Share capital         60,177,975         60,177,975           Share premium         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,525         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         383,753         413,109           Term loan         3,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           Current Liabilities         3,923,814         5,412,385           Other payables         3,923,814         5,412,385           Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Total LiABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         173,752,056  <	,		
Share premium         21,751,724         21,751,724           Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,525         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         383,753         413,109           Term loan         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           42,269,398         43,961,114         Current Liabilities           Trade payables         3,923,814         5,412,385           Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           27,651,221         26,255,097           TOTAL LIABILITIES         170,231,572         173,752,056		60,177,975	60,177,975
Exchange rate reserve         (1,469)         (3,217)           Retained profits         18,308,525         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           42,269,398         43,961,114           Current Liabilities         3,923,814         5,412,385           Other payables         3,923,814         5,412,385           Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056			21,751,724
Retained profits         18,308,525         21,495,335           Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           Current Liabilities         3,229,167         3,229,167           Trade payables         3,923,814         5,412,385           Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           27,651,221         26,255,097           TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056			
Total Equity         100,236,755         103,421,817           Minority interests         74,198         114,028           Total Equity Attributable To Equity Holders Of The Company         100,310,953         103,535,845           Non-Current Liabilities         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           42,269,398         43,961,114           Current Liabilities         3,923,814         5,412,385           Other payables         3,923,814         5,412,385           Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056			
Non-Current Liabilities         38,656,478         40,318,838           Hire purchase         383,753         413,109           Deferred taxation         3,229,167         3,229,167           Current Liabilities         42,269,398         43,961,114           Current Liabilities         3,923,814         5,412,385           Other payables         31,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           27,651,221         26,255,097           TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056		100,236,755	103,421,817
Non-Current Liabilities         Term loan       38,656,478       40,318,838         Hire purchase       383,753       413,109         Deferred taxation       3,229,167       3,229,167         Current Liabilities       42,269,398       43,961,114         Current Liabilities       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056			
Term loan       38,656,478       40,318,838         Hire purchase       383,753       413,109         Deferred taxation       3,229,167       3,229,167         42,269,398       43,961,114         Current Liabilities         Trade payables       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056	Total Equity Attributable To Equity Holders Of The Company	100,310,953	103,535,845
Term loan       38,656,478       40,318,838         Hire purchase       383,753       413,109         Deferred taxation       3,229,167       3,229,167         42,269,398       43,961,114         Current Liabilities         Trade payables       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056	Non Current Liabilities		
Hire purchase       383,753       413,109         Deferred taxation       3,229,167       3,229,167         42,269,398       43,961,114         Current Liabilities         Trade payables       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056		38 656 <b>4</b> 78	40 318 838
Deferred taxation         3,229,167         3,229,167           42,269,398         43,961,114           Current Liabilities         3,923,814         5,412,385           Trade payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056		· · ·	
Current Liabilities         Trade payables       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056			
Current Liabilities         Trade payables       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056	Doloned taxation		
Trade payables       3,923,814       5,412,385         Other payables       11,348,180       10,380,197         Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056	Current Liabilities	,,	
Other payables         11,348,180         10,380,197           Term loan         7,486,455         7,678,563           Hire purchase         112,604         112,604           Bank overdraft         4,780,168         2,671,290           Tax payable         -         58           27,651,221         26,255,097           TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056		3,923,814	5,412,385
Term loan       7,486,455       7,678,563         Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056			
Hire purchase       112,604       112,604         Bank overdraft       4,780,168       2,671,290         Tax payable       -       58         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056			
Bank overdraft Tax payable       4,780,168       2,671,290         Tax payable       -       58         27,651,221       26,255,097         TOTAL LIABILITIES       69,920,619       70,216,211         TOTAL EQUITY AND LIABILITIES       170,231,572       173,752,056	Hire purchase		112,604
TOTAL LIABILITIES         27,651,221 26,255,097 70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572 173,752,056			
TOTAL LIABILITIES         69,920,619         70,216,211           TOTAL EQUITY AND LIABILITIES         170,231,572         173,752,056	Tax payable	<u>-</u>	
TOTAL EQUITY AND LIABILITIES 170,231,572 173,752,056		27,651,221	
	TOTAL LIABILITIES	69,920,619	70,216,211
NET ASSETS PER TEN SEN ORDINARY SHARE (RM) 0.1667 0.1720	TOTAL EQUITY AND LIABILITIES	170,231,572	173,752,056
	NET ASSETS PER TEN SEN ORDINARY SHARE (RM)	0.1667	0.1720

The restatement of the 2009 Statement of Financial Position reflects the change in the Group's accounting policy for classification of prepaid lease payments for land required by FRS 117: Leases, as explained in Note A2 (ii).

(The unaudited condensed consolidated balance sheet should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying notes attached to the interim financial report)

# INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2010

PERIOD	CONDENSED CONSOLIDATED CASH FLOW STATEME	ENT (UNAUDITED)	
Cash flows from operating activities   Loss before taxation   (2,595,236)   (3,797,995)		PERIOD ENDED	ENDED
Cash flows from operating activities         (2,595,236)         (8,797,995)           Loss before taxation         (2,595,236)         (8,797,995)           Adjustments for Non-cash items         1,283,373         8,308,790           Gain on disposal of property, plant and equipment         493         (736)           Share of (loss)/profit in associate company         493         (736)           Interest paid         638,439         1,744,741           Interest income         (18,570)         (151,638)           Operating (loss) / profit before changes in working capital         (693,501)         1,430,194           Changes in working capital:		_	
Loss before taxation		(UNAUDITED)	(AUDITED)
Adjustments for Non-cash items 1,283,373 8,808,790 Gain on disposal of property, plant and equipment . (172,968) (172,968) (173,968) (17	· · · · · · · · · · · · · · · · · · ·		
Non-cash Items	Loss before taxation	(2,595,236)	(8,797,995)
Non-cash Items	Adjustments for		
Share of (loss)/profit in associate company		1,283,373	8,808,790
Interest paid	Gain on disposal of property, plant and equipment	=	(172,968)
Interest income	Share of (loss)/profit in associate company	493	(736)
Changes in working capital:   Net change in current assets   490,362   16,872,273     Net change in current liabilities   (520,588)   (3,193,516)     Cash (used in) / generated from operations   (723,727)   15,108,951     Interest paid   (636,439)   (1,744,741)     Interest received   18,570   151,638     Income tax paid   (204,915)   (653,743)     Net cash (used in) / generated from operating activities   (1,546,511)   12,362,105     Cash flows from investing activities   (901,761)   (44,344,123)     Nurse sponsorship incurred, net of receipts   (10,33,877)     Proceeds from disposal of property, plant and equipment   (901,761)   (44,344,123)     Nurse sponsorship incurred, net of receipts   (10,33,877)     Proceeds from disposal of property, plant and equipment   (335,300   10,338)     Investment in associate company   (215,385)     Issuance of subsidiary's ordinary shares   48,880     Other investment redeemed/(purchased)   383,883   (2,498,713)     Net cash used in investing activities   (517,878)   (47,707,918)     Cash flows from financing activities   (1,854,468)   (17,937,401     Repayment of hire purchase   (29,356)   (74,287)     Net cash (used in)/ generated from financing activities   (1,883,824)   (1,17,775     Net decrease in cash and cash equivalents   (3,948,213)   (18,728,038)     Cash and cash equivalents at beginning of financial period/year   2,592,561   21,302,176     Effects of exchange rate changes on cash and bank balances   1,748   18,423     Cash and cash equivalents at end of financial period/year   (1,353,904)   2,592,561     NOTES TO CASH FLOW STATEMENT   Cash and cash equivalents comprise:   Cash and bank balances   3,426,264   5,263,851   Sank overdraft   4,780,168   2,671,290	Interest paid	<b>6</b> 36,4 <b>3</b> 9	1,744,741
Changes in working capital:         490,362         16,872,273           Net change in current assets         (520,588)         (3,193,516)           Cash (used in) / generated from operations         (723,727)         15,108,951           Interest paid         (636,439)         (1,744,741)           Interest received         18,570         1516,838           Income tax paid         (204,915)         (653,743)           Net cash (used in)/generated from operating activities         (1,546,511)         12,862,105           Cash flows from investing activities         (901,761)         (44,344,123)           Nurse sponsorship incurred, net of receipts         -         (1,033,877)           Proceeds from disposal of property, plant and equipment investment in associate company         -         (215,385)           Investment in associate company         -         (215,385)           Issuance of subsidiary's ordinary shares         -         48,880           Other investment redeemed/(purchased)         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         -         (1,805,339)           Dividends paid         -         (1,854,468)         17,997,401           Repayment) / drawd	Interest income	(18,570)	(151,638)
Net change in current assets         490,382         16,872,273           Net change in current liabilities         (520,588)         (3,193,516)           Cash (used in) / generated from operations         (723,727)         15,108,951           Interest paid         (636,439)         (1,744,741)           Interest received         18,570         151,638           Income tax paid         (204,915)         (653,743)           Net cash (used in)/generated from operating activities         (1,546,511)         12,862,105           Cash flows from investing activities         (44,344,123)         12,862,105           Nurse sponsorship incurred, net of receipts         -         (1,033,877)           Proceeds from disposal of property, plant and equipment in associate company         -         (215,385)           Issuance of subsidiary's ordinary shares         -         (48,880)           Other investment redeemed/(purchased)         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         -         (1,805,339)           (Repayment) / drawdown of term loan         (1,854,468)         17,997,401           Repayment of hire purchase         (29,356)         (74,287)           Net cash (used in)	Operating (loss) / profit before changes in working capital	(693,501)	1,430,194
Net change in current assets         490,382         16,872,273           Net change in current liabilities         (520,588)         (3,193,516)           Cash (used in) / generated from operations         (723,727)         15,108,951           Interest paid         (636,439)         (1,744,741)           Interest received         18,570         151,638           Income tax paid         (204,915)         (653,743)           Net cash (used in)/generated from operating activities         (1,546,511)         12,862,105           Cash flows from investing activities         (44,344,123)         12,862,105           Nurse sponsorship incurred, net of receipts         -         (1,033,877)           Proceeds from disposal of property, plant and equipment in associate company         -         (215,385)           Issuance of subsidiary's ordinary shares         -         (48,880)           Other investment redeemed/(purchased)         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         -         (1,805,339)           (Repayment) / drawdown of term loan         (1,854,468)         17,997,401           Repayment of hire purchase         (29,356)         (74,287)           Net cash (used in)	Changes in working capital:	•	
Net change in current liabilities		490,362	16,872,273
Interest paid Interest received Interest received Interest received Interest received Income tax paid (204,915) (663,743)  Net cash (used in)/generated from operating activities  Cash flows from investing activities  Acquisition of property, plant and equipment Acquisition of property, plant and equipment Nurse sponsorship incurred, net of receipts Acquisition of property, plant and equipment Investment in associate company Investment in associate company Investment in associate company Investment redeemed/(purchased) Investment redeeme		(520,588)	
Interest received   18,570   151,638   Income tax paid   (204,915)   (663,743)   (74,341,23)   (	Cash (used in) / generated from operations	(723,727)	15,108,951
Income tax paid   (204,915)   (663,743)   Net cash (used in)/generated from operating activities   (1,546,511)   12,862,105	Interest paid	(636,439)	(1,744,741)
Net cash (used in)/generated from operating activities         (1,546,511)         12,862,105           Cash flows from investing activities         (901,761)         (44,344,123)           Acquisition of property, plant and equipment         (901,761)         (44,344,123)           Nurse sponsorship incurred, net of receipts         (1,033,877)           Proceeds from disposal of property, plant and equipment         335,300           Investment in associate company         (215,385)           Issuance of subsidiary's ordinary shares         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         (517,878)         (47,707,918)           Cash flows from financing activities         (1,854,468)         17,997,401           Repayment) / drawdown of term loan         (1,854,468)         17,997,401           Repayment of hire purchase         (29,358)         (74,287)           Net cash (used in)/ generated from financing activities         (1,854,468)         16,117,775           Net decrease in cash and cash equivalents         (3,948,213)         (18,728,038)           Cash and cash equivalents at beginning of financial period/year         2,592,561         21,302,176           Effects of exchange rate changes on cash and bank balances         1,74	Interest received	18,570	151,638
Cash flows from investing activities  Acquisition of property, plant and equipment Nurse sponsorship incurred, net of receipts Proceeds from disposal of property, plant and equipment Nurse sponsorship incurred, net of receipts Proceeds from disposal of property, plant and equipment Nurse sponsorship incurred, net of receipts Proceeds from disposal of property, plant and equipment Nurse sponsorship incurred, net of receipts Net sand cash equivalents at end of financial period/year  Cash flows from financing activities  Cash flows from financing activities  Dividends paid (Repayment) / drawdown of term loan (1,854,468) (29,356) (74,287) Net cash (used in)/ generated from financing activities  Net decrease in cash and cash equivalents  Cash and cash equivalents at beginning of financial period/year  Effects of exchange rate changes on cash and bank balances  Cash and cash equivalents at end of financial period/year  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances  3,426,264 5,263,851 Bank overdraft 4,780,168 5,263,851 Bank overdraft 4,780,168 5,263,851 Bank overdraft			
Acquisition of property, plant and equipment Nurse sponsorship incurred, net of receipts - (1,033,877) Proceeds from disposal of property, plant and equipment Investment in associate company Investment in associate company Issuance of subsidiary's ordinary shares Other investment redeemed/(purchased) Investment redeemed/(purchased) Issuance of subsidiary's ordinary shares Issuance of subsidiary satisfactor (1,853,384) Issuance of subsidiary satisfactor (1,855,385) Issuance of subsidiary sordinary shares Issuance of subsidiary satisfactor (1,855,385) Issuance of subsidiary sati	Net cash (used in)/generated from operating activities	(1,546,511)	12,862,105
Acquisition of property, plant and equipment Nurse sponsorship incurred, net of receipts - (1,033,877) Proceeds from disposal of property, plant and equipment Investment in associate company Investment in associate company Issuance of subsidiary's ordinary shares Other investment redeemed/(purchased) Net cash used in investing activities  Cash flows from financing activities Dividends paid (Repayment) / drawdown of term loan (Repayment) / drawdown of term loan Repayment of hire purchase Net cash (used in)/ generated from financing activities (1,853,824)  Net decrease in cash and cash equivalents  Cash and cash equivalents at beginning of financial period/year  Effects of exchange rate changes on cash and bank balances  Cash and cash equivalents at end of financial period/year  Cash and cash equivalents at end of financial period/year  Cash and cash equivalents at end of financial period/year  Cash and cash equivalents comprise: Cash and bank balances  3,426,264 5,263,851 Bank overdraft  4,780,168 2,671,290	Cook flows from investing activities		
Nurse sponsorship incurred, net of receipts         (1,033,877)           Proceeds from disposal of property, plant and equipment investment in associate company         -         (215,385)           Issuance of subsidiary's ordinary shares         -         48,880           Other investment redeemed/(purchased)         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         -         (1,805,339)           Dividends paid (Repayment) / drawdown of term loan (1,854,468)         17,997,401         (74,287)           Net cash (used in)/ generated from financing activities         (1,883,824)         16,117,775           Net decrease in cash and cash equivalents         (3,948,213)         (18,728,038)           Cash and cash equivalents at beginning of financial period/year         2,592,561         21,302,176           Effects of exchange rate changes on cash and bank balances         1,748         18,423           Cash and cash equivalents at end of financial period/year         (1,353,904)         2,592,561           NOTES TO CASH FLOW STATEMENT         Cash and bank balances         3,426,264         5,263,851           Bank overdraft         4,780,168         2,671,290		(901.761)	(44 344 123)
Proceeds from disposal of property, plant and equipment in associate company investment in associate company issuance of subsidiary's ordinary shares         - (215,385)           Issuance of subsidiary's ordinary shares         - 48,880           Other investment redeemed/(purchased)         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         - (1,805,339)         (74,707,918)           Cash glows from financing activities         - (1,854,468)         17,997,401           Repayment) / drawdown of term loan         (1,854,468)         17,997,401           Repayment of hire purchase         (29,356)         (74,287)           Net cash (used in)/ generated from financing activities         (1,883,824)         16,117,775           Net decrease in cash and cash equivalents         (3,948,213)         (18,728,038)           Cash and cash equivalents at beginning of financial period/year         2,592,561         21,302,176           Effects of exchange rate changes on cash and bank balances         1,748         18,423           Cash and cash equivalents at end of financial period/year         (1,353,904)         2,592,561           NOTES TO CASH FLOW STATEMENT         Cash and cash equivalents comprise:         3,426,264         5,263,851           Cash and bank balances		(001,701)	
Investment in associate company   C215,385     Issuance of subsidiary's ordinary shares   A8,880     Other investment redeemed/(purchased)   383,883   (2,498,713)     Net cash used in investing activities   (517,878)   (47,707,918)      Cash flows from financing activities     Dividends paid   (1,805,339)     (Repayment) / drawdown of term loan   (1,854,468)   17,997,401     Repayment of hire purchase   (29,356)   (74,287)     Net cash (used in)/ generated from financing activities   (1,883,824)   16,117,775    Net decrease in cash and cash equivalents   (3,948,213)   (18,728,038)     Cash and cash equivalents at beginning of financial period/year   2,592,561   21,302,176     Effects of exchange rate changes on cash and bank balances   1,748   18,423     Cash and cash equivalents at end of financial period/year   (1,353,904)   2,592,561     NOTES TO CASH FLOW STATEMENT     Cash and cash equivalents comprise:   Cash and bank balances   3,426,264   5,263,851     Bank overdraft   4,780,168   2,671,290		_	
Sauance of subsidiary's ordinary shares			
Other investment redeemed/(purchased)         383,883         (2,498,713)           Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         (1,805,339)           Dividends paid (Repayment) / drawdown of term loan (Repayment of hire purchase (29,356) (74,287)         (1,854,468) (17,997,401           Net cash (used in)/ generated from financing activities         (1,883,824) (16,117,775           Net decrease in cash and cash equivalents         (3,948,213) (18,728,038)           Cash and cash equivalents at beginning of financial period/year         2,592,561 (1,302,176)           Effects of exchange rate changes on cash and bank balances         1,748 (1,353,904) (1,353,904) (1,353,904) (1,353,904) (1,353,904)         2,592,561           NOTES TO CASH FLOW STATEMENT         Cash and cash equivalents comprise:         3,426,264 (5,263,851) (1,290,168) (1,290,168) (1,290,168)           Cash and bank balances         3,426,264 (5,263,851) (1,290,168) (1,290,168) (1,290,168) (1,290,168) (1,290,168)		•	• • •
Net cash used in investing activities         (517,878)         (47,707,918)           Cash flows from financing activities         (1,805,339)           Dividends paid (Repayment) / drawdown of term loan (1,854,468)         17,997,401           Repayment of hire purchase (29,356)         (74,287)           Net cash (used in)/ generated from financing activities         (1,883,824)         16,117,775           Net decrease in cash and cash equivalents         (3,948,213)         (18,728,038)           Cash and cash equivalents at beginning of financial period/year         2,592,561         21,302,176           Effects of exchange rate changes on cash and bank balances         1,748         18,423           Cash and cash equivalents at end of financial period/year         (1,353,904)         2,592,561           NOTES TO CASH FLOW STATEMENT         (2,592,561)         3,426,264         5,263,851           Cash and bank balances         3,426,264         5,263,851           Bank overdraft         4,780,168         2,671,290		383.883	-
Dividends paid (Repayment) / drawdown of term loan (Repayment) / drawdown of term loan (Repayment of hire purchase (Repayment) / drawdown of term loan (Repayment) / drawdown			
Dividends paid (Repayment) / drawdown of term loan (Repayment) / drawdown of term loan (Repayment of hire purchase (Repayment) / drawdown of term loan (Repayment) / drawdown			
(Repayment) / drawdown of term loan Repayment of hire purchase Repayment of hire purchase Net cash (used in)/ generated from financing activities  (1,883,824)  (1,883,824)  (1,883,824)  (1,883,824)  (1,8728,038)  Cash and cash equivalents at beginning of financial period/year  (1,3948,213)  (18,728,038)  Cash and cash equivalents at beginning of financial period/year  (1,392,176)  Effects of exchange rate changes on cash and bank balances  (1,353,904)		_	. (1.805.330)
Repayment of hire purchase Net cash (used in)/ generated from financing activities  (1,883,824)  Net decrease in cash and cash equivalents  (3,948,213)  (18,728,038)  Cash and cash equivalents at beginning of financial period/year  Effects of exchange rate changes on cash and bank balances  1,748  18,423  Cash and cash equivalents at end of financial period/year  (1,353,904)  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances  3,426,264  5,263,851  Bank overdraft  4,780,168  2,671,290		/1 85 <i>A (</i> 68)	
Net cash (used in)/ generated from financing activities (1,883,824) 16,117,775  Net decrease in cash and cash equivalents (3,948,213) (18,728,038)  Cash and cash equivalents at beginning of financial period/year 2,592,561 21,302,176  Effects of exchange rate changes on cash and bank balances 1,748 18,423  Cash and cash equivalents at end of financial period/year (1,353,904) 2,592,561  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances 3,426,264 5,263,851 Bank overdraft 4,780,168 2,671,290			• -
Net decrease in cash and cash equivalents  Cash and cash equivalents at beginning of financial period/year  Effects of exchange rate changes on cash and bank balances  Cash and cash equivalents at end of financial period/year  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances  Sank overdraft  Cash and bank balances  Sank overdraft  Cash and cash equivalents comprise: Cash and bank balances  Sank overdraft  Cash and cash equivalents comprise: Cash and bank balances  Sank overdraft  Cash and cash equivalents comprise: Cash and bank balances  Sank overdraft			
Cash and cash equivalents at beginning of financial period/year 2,592,561 21,302,176  Effects of exchange rate changes on cash and bank balances 1,748 18,423  Cash and cash equivalents at end of financial period/year (1,353,904) 2,592,561  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances 3,426,264 5,263,851 Bank overdraft 4,780,168 2,671,290	Net bash fasca till generated from manoring assistation	(1,000,000)	
Effects of exchange rate changes on cash and bank balances  Cash and cash equivalents at end of financial period/year  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances Bank overdraft  1,748  18,423  1,748  1,748  1,748  2,592,561  3,426,264  5,263,851  4,780,168  2,671,290	Net decrease in cash and cash equivalents	(3,948,213)	(18,728,038)
Cash and cash equivalents at end of financial period/year (1,353,904) 2,592,561  NOTES TO CASH FLOW STATEMENT Cash and cash equivalents comprise: Cash and bank balances 3,426,264 5,263,851 Bank overdraft 4,780,168 2,671,290	Cash and cash equivalents at beginning of financial period/year	2,592,561	21,302,176
NOTES TO CASH FLOW STATEMENT  Cash and cash equivalents comprise:  Cash and bank balances  Bank overdraft  3,426,264 5,263,851 4,780,168 2,671,290	Effects of exchange rate changes on cash and bank balances	1,748	18,423
Cash and cash equivalents comprise:         3,426,264         5,263,851           Cash and bank balances         4,780,168         2,671,290	Cash and cash equivalents at end of financial period/year	(1,353,904)	2,592,561
Cash and cash equivalents comprise:         3,426,264         5,263,851           Cash and bank balances         4,780,168         2,671,290	NOTES TO CASH FLOW STATEMENT		
Cash and bank balances       3,426,264       5,263,851         Bank overdraft       4,780,168       2,671,290	***		
Bank overdraft 4,780,168 2,671,290		3,426,264	5,263,851
	Total cash and cash equivalents	(1,353,904)	2,592,561

(The unaudited condensed consolidated cash flow statements should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying notes attached to the interim financial report)

INTERIM FINANCIAL REPORT FOR THE

FIRST QUARTER ENDED 31 MARCH 2010

# CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

	Share Capital RM	Share Premium RM	Foreign Exchange Translation Reserve RM	Distributable Retained Profits RM	Total RM	Minority Interests RM	Total Equity RM
At 1 January 2010	60,177,975	21,751,724	(3,217)	21,495,335	103,421,817	114,028	103,535,845
Effect of adopting FRS 139	<u> </u>		-	(570,842).	(570,842)		(570,842)
As at 1 January 2010, restated	60,177,975	21,751,724	(3,217)	20,924,493	102,850,975	114,028	102,965,003
Net loss for the period	-	-	-	(2,615,968)	(2,615,968)	(39,830)	(2,655,798)
Foreign exchange reserve	<del>-</del>		1,748	-	1,748	-	1,748
At 31 March 2010	60,177,975	21,751,724	(1,469)	18,308,525	100,236,755	74,198	100,310,953
							<del>;</del>
At 1 January 2009	60,177,975	21,751,724	(23,462)	32,103,833	114,010,070	7,656	114,017,726
Net loss for the year	-		-	(8,803,159)	(8,803,159)	57,492	(8,745,667)
Shares subscribed by minority shareholders	-	-	-	<del>.</del>	**	48,880	48,880
Foreign exchange reserve	~	-	20,245	-	20,245		20,245
Dividends pald	-	**	-	(1,805,339)	(1,805,339)	<del>.</del>	(1,805,339)
At 31 December 2009	60,177,975	21,751,724	(3,217)	21,495,335	103,421,817	114,028	103,535,845

(The unaudited condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying notes attached to the interim financial report)

### NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FOURTH QUARTER ENDED 31 MARCH 2010

# A EXPLANATORY NOTES PURSUANT TO FINANCIAL REPORTING STANDARD ("FRS") 134 INTERIM FINANCIAL REPORTING

#### A1 BASIS OF PREPARATION

The interim report have been prepared in accordance with the requirements of Financial Reporting Standards (FRS) 134 "Interim Financial Reporting" and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad for the Main Board.

The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements of the Group for the year ended 31 December 2009. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2009.

#### A2 CHANGES IN ACCOUNTING POLICIES

The significant accounting policies adopted are consistent with those of the audited financial statements for the financial year ended 31 December 2009, except for the adoption of the following new FRSs and IC Interpretations with effect from 1 January 2010:

FRS 4	Insurance Contracts
FRS 7	Financial Instruments: Disclosures
FRS 8	Operating Segments
FRS 101	Presentation of Financial Statements (Revised)
FRS 123	Borrowing Costs (Revised)
FRS 132	Financial Instruments: Presentation (Revised)
FRS 139	Financial Instruments: Recognition and Measurement
Amendment to FRS1	First-time Adoption of Financial Reporting Standard
Amendment to FRS2	Share-based Payment -Vesting conditions and Cancellations
Amendment to FRS7	Financial Instruments: Disclosures
Amendment to FRS8	Operating Segments
Amendment to FRS107	Statement of Cash Flows
Amendment to FRS108	Accounting Policies, Changes in Accounting Estimates and Errors
Amendment to FRS110	Events after the Reporting Period
Amendment to FRS116	Property, Plant & Equipment
Amendment to FRS117	Leases
Amendment to FRS118	Revenue
Amendment to FRS119	Employee Benefits
Amendment to FRS127	Consolidated and Separate Financial Statements
Amendment to FRS132	Financial Instruments: Presentation
Amendment to FRS134	Interim Financial Reporting
Amendment to FRS136	Impairment of Assets
Amendment to FRS138	Intangible Assets
IC Int.9	Reassessment of Embedded Derivatives
IC Int.10	Interim Financial Reporting and Impairment

# A2 CHANGES IN ACCOUNTING POLICIES (CONT'D)

The principal effects of the changes in presentation, changes in methods of computation and in accounting policies resulting from the adoption of the new and revised FRSs, IC Interpretations and Amendments are set out below:

#### i) FRS 101: Presentation of Financial Statements

The FRS 101 introduces the statement of comprehensive income: presenting all items of income and expense recognized in the income statement, together with all the other items of recognized income and expense, either in one single statement, or in two linked statement. In addition, a statement of financial position is required at the beginning of the earliest comparative period following a change in accounting policy, the correction of an error or the reclassification of items in the financial statement. The FRS did not have any impact on the financial position and result of the Group.

#### ii) FRS 117: Leases

The amendments requires entity with existing leases of land and building to reassess the classification of land as finance or operating lease. Following the amendments, the Group has reclassified the existing leasehold land to property, plant and equipment, with no effect on reported profit or equity. However, as a result of the adoption of the amendments, comparative balances as at 31 December 2009 has been restated as follows:

	As previously reported	Effect of adopting amendments to FRS117	As restated	
,	RM	RM	RM	
Property, plant and equipment	116,429,729	18,783,330	135,213,059	
Prepaid land lease payments	18,783,330	(18,783,330)		

### iii) FRS 139: Financial Instruments: Recognition and Measurement

The FRS 139 establishes principles for recognizing and measuring financial assets, financial liabilities and some contracts to buy and sell non-financial items. This FRS did not have any significant impact on the financial position and results of the Group

### Impact on opening balance

In accordance with the transitional provisions of FRS139, the changes are applied prospectively and the comparative as at 31 December 2009 are not restated. Instead, the changes have been accounted for by restating the following opening balances in the Statement of Financial Position as at 1 January 2010.

## iii) FRS 139: Financial Instruments: Recognition and Measurement (cont'd)

	Previously stated RM	Effect of FRS139 RM	As restated RM
<u>Assets</u>			
Long term receivables	_	1,472,251	1,472,251
Trade receivable	6,358,070	(2,043,092)	4,314,978
<u>Equity</u>			
Retained earnings	21,495,335	(570,842)	20,924,493

#### A3 AUDIT REPORT OF THE PRECEDING ANNUAL FINANCIAL STATEMENTS

There were no audit qualifications in the annual financial statements of the Company and its subsidiaries for the financial year ended 31 December 2009.

#### A4 SEASONALITY OR CYCLICALITY OF OPERATIONS

The business of the Group is not significantly affected by any seasonal or cyclical factors.

#### A5 UNUSUAL ITEMS

During the current quarter under review, there were no items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

#### A6 CHANGE IN ESTIMATES

There was no material changes in the nature and amount of estimates reported that have a material effect in the current quarter under review.

#### A7 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current quarter under review.

#### A8 PROPERTY, PLANT AND EQUIPMENT

There was no revaluation on any of the Group's property, plant and equipment during the current quarter under review.

#### A9 DIVIDENDS PAID

No dividend was paid in the current financial period ended 31 March 2010.

#### A10 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and currently is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital. The Group also provides fertility and gynecological services, stem cell banking and therapy, and research and development in life sciences.

#### A11 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There were no material events subsequent to 31 December 2009 and up to the date of this report.

#### A12 CHANGES IN THE COMPOSITION OF THE GROUP

Not applicable.

#### A13 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

The Company has provided corporate guarantees to a licensed financial institution for banking facilities and suppliers amounting to RM58.0 million and RM3.0 million respectively. The guarantees were granted for the benefit of a wholly owned subsidiary company. The banking facilities are primarily for financing the construction and equipping of the Group's flagship hospital. Arising from this, the Company is contingently liable for the amount utilized by its subsidiary company of approximately RM53.93 million as at 31 March 2010.

### A14 CAPITAL COMMITMENTS

Capital expenditures not provided for in the interim financial report as at 31 March 2010 are as follows:

	RM '000
Approved and contracted for	75,944
Paid up to 31 March 2010	(67,462)
	8,482

#### A15 SIGNIFICANT RELATED PARTY TRANSACTIONS

The directors are of the opinion that the transactions below have been entered into in the normal course of business and have been established on the terms and conditions that are not materially different from those obtainable in transactions with unrelated parties.

The Company and/or its subsidiaries	Transacting Parties	Relationship	Nature of Transactions	Current Quarter Ended 31 Mar 10 RM	Cumulative Quarter Ended 31 Mar 10 RM
TMC Women's Specialist Holdings Sdn Bhd	Dato' Dr Lee Soon Soo	Director and substantial shareholder of the Company	Rental of premise	3,600	3,600
IVF Technologie s sdn bhd	Dato' Dr Lee Soon Soo	Director and substantial shareholder of the Company	Rental of signage space	1,200	1,200

# B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES")

### **B1** REVIEW OF PERFORMANCE

For the 3 months ended 31 March 2010 ("1Q10"), group revenue grew 21.51% to RM12.37 million compared to RM10.18 million achieved in the corresponding period in the previous year. The improvement was mainly due to the increased revenues from the Group's flagship multi disciplinary tertiary hospital, as a result of the hospital now operating with more comprehensive services during the quarter under review than were offered in 1Q09. In addition, promotional activities of the hospital during the financial year ended 31 December 2009 helped in the market awareness of the hospital.

However the quarter under review saw the Group registering a loss after taxation and minority interests of RM2.62 million as compared to a loss after tax and minority interests of RM2.75 million recorded in the corresponding period in the previous year. The loss was due largely to the increased operating expenses, in tandem with expanded facilities and services offered at the hospital, as well as the higher depreciation and finance costs during the quarter.

Review of	Current	Preceding	Changes	Current	Preceding	Changes
performance	quarter	year	%	period	year	%
	(RM'mil)	corresponding		(RM'mil)	corresponding	
		quarter			period	
		(RM'mil)			(RM'mil)	
Revenue	12.37	10.18	21.51%	12.37	10.18	21.51%
(Loss)/Profit after				4.4		
taxation and minority						
interest	(2.62)	(2.75)	4.73%	(2.62)	(2.75)	4.73%

# B2 COMPARISON WITH PRECEDING QUARTER'S RESULTS

The Group recorded a revenue and loss before taxation of RM12.37 million and RM2.62 million respectively for 1Q10 as compared to a revenue of RM14.29 million and loss before taxation of RM1.74 million in the preceding quarter ("4Q09"). The decreased financial performance was mainly due to a quieter quarter which coincided with the festive season.

## B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 31 DECEMBER 2010

The Board is positive that the Group's revenue base will continue to increase in FY2010, spurred by the increased number of specialist doctors and support personnel at the flagship hospital, as well as ongoing promotional activities of the hospital's advanced facilities and services. In addition, the Group's other segments of fertility treatment, wellness program, and stem cell services will continue to contribute to the group revenue.

#### B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

Not applicable.

#### **B5 TAXATION**

	INDIVIDUAL	INDIVIDUAL QUARTER QUARTER QUARTER		CUMULATIVE QUARTER		
	QUARTER			PERIOD		
	ENDED	ENDED	ENDED	ENDED		
	31 Mar 2010	31 Mar 2009	31 Mar 2010	31 Mar 2009		
Malaysian income tax:						
<ul> <li>current taxation</li> </ul>	60,562	(15,345)	_	(15,345)		
- prior year taxation	-	-		_		
<ul> <li>deferred taxation</li> </ul>	-		-	-		
Total	60,562	(15,345)	-	(15,345)		

#### B6 PROFIT ON SALE OF UNQUOTED INVESTMENTS AND/OR PROPERTIES

There were no purchases or disposals of unquoted investment and/or properties during the current financial period under review.

#### **B7 QUOTED SECURITIES**

There were no purchases or disposals of quoted securities during the current financial period under review.

## **B8** SIGNIFICANT EVENT

There was no significant event in the quarter under review.

## B9 STATUS OF CORPORATE PROPOSAL

There were no corporate proposals in this quarter except the following:

On 18 September 2008, the Company entered into a Memorandum of Understanding with Berjaya Corporation Berhad and Viet Ha Corporation to establish a formal relationship in order to jointly carry out activities relating to the design, construction, furnishing, equipping and operating of a hospital in or near Hanoi, Vietnam.

Further to the announcement made on 18 September 2008, the parties to the Memorandum of Understanding (MOU) have mutually agreed to extend the duration of the MOU for a further period of twelve (12) months from 17 September 2009 until 17 September 2010.

There is no material development since the last announcement.

#### **B10 BORROWINGS**

The Group's borrowings as at 31 March 2010 are as follows:-

	Long Term (RM million)	Short Term (RM million)	Total (RM million)
Secured	38.66	12.27	50.93
Unsecured			
Total	38.66	12.27	50.93

#### B11 OFF BALANCE SHEET FINANCIAL INSTRUMENTS

There were no off balance sheet financial instruments as at the date of this report.

#### **B12 MATERIAL LITIGATION**

There were no material litigations as at the date of this report.

#### **B13 DIVIDENDS**

The Board had declared a first and final single tier dividend of 3% per ordinary share of RM0.10 each for the financial year ended 31 December 2009. The payment of the dividend is subject to the approval of shareholders at the forthcoming Annual General Meeting and if approved, the dividend will be paid on 28 July 2010 to shareholders whose names appear in the Record of Depositors of the Company at the close of business on 25 June 2010.

#### B14 EARNINGS PER SHARE

- Diluted	N/A	N/A	N/A	N/A
(LPS)/EPS (sen) - Basic	(0.43)	(0.46)	(0.43)	(0.46)
shares in issue ('000)	601,780	601,780	601,780	601,780
Weighted average number of ordinary				
Net (loss) / profit attributable to shareholders	(2,615,968)	(2,752,619)	(2,615,968)	(2,752,619)
Basic earnings per share (EPS)	31 Mar 2010	31 Mar 2009	31 Mar 2010	31 Mar 2009
	ENDED	ENDED	ENDED	
	QUARTER	QUARTER	PERIOD	PERIOD
	INDIVIDUAL QUARTER		CUMULATIVE QUARTE	